1. Introduction 1.1 Scope of the Study 1.2 Executive Summary 2. Research Approach and Methodology 2.1 Key Deliverables of the Study 2.2 Study Assumptions 2.3 Analysis Methodology 2.4 Research Phases 3. Market Insights 3.1 Market Overview 3.2 Industry Attractiveness - Porter's Five Forces Analysis 3.2.1 Bargaining Power of Suppliers 3.2.2 Bargaining Power of Consumers 3.2.3 Threat of New Entrants 3.2.4 Threat of Substitute Products or Services 3.2.5 Competitive Rivalry among Existing Competitors 3.3 Industry Value Chain Analysis 3.4 Industry Policies 4. Market Dynamics 4.1 Market Drivers 4.1.1 Increasing Outsourcing Volume by Big Pharmaceutical Companies 4.1.2 Expansion in the Service Offering of CMOS 4.1.3 Advent of CDMO Model into the Market 4.1.4 Increasing Investment in R&D 4.2 Market Restraints 4.2.1 Increasing Lead Time and Logistics Costs 4.2.2 Stringent Regulatory Requirements 4.2.3 Capacity Utilization Issues Affecting the Profitability of CMOS 5. Technology Snapshot 5.1 Dosage Formulation Technologies 5.1.1 Abuse-deterrent Formulation Technology 5.1.2 Lipid Martiparticulate (LMP) Technology 5.1.3 Dry Powder Inhalation Technology 5.1.4 Force Control Agent Technology 5.1.5 High-potency Drug Formulation Technology 5.1.6 Fluidized Bed Coating Technology 5.1.7 Form Eze Technology 5.2 Dosage Forms by Route of Administration 5.2.1 Oral 5.2.2 Topical 5.2.3 Parental 5.2.4 Rectal 5.2.5 Vaginal 5.2.6 Inhaled 5.2.7 Ophthalmic 5.2.8 Otic 6. Global Pharmaceutical Contract Manufacturing Market Segmentation 6.1 By Service Type 6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing 6.1.2 Finished Dosage Formulation (FDF) Development & Manufacturing 6.1.2.1 Solid Dose Formulation 6.1.2.2 Liquid Dose Formulation 6.1.2.3 Injectable Dose Formulation 6.1.3 Secondary Packaging 6.2 By Region 6.2.1 North America 6.2.1.1 By Service Type 6.2.1.1.1 API 6.2.1.1.2 FDF 6.2.1.1.2.1 Solid Dose Formulation 6.2.1.1.2.2 Semi-solid/Liquid dose formulation 6.2.1.1.2.3 Injectable Dose Formulation 6.2.1.1.3 Packaging 6.2.1.2 By Country 6.2.1.2.1 United States 6.2.1.2.2 Canada 6.2.2 Europe 6.2.2.1 By Service Type 6.2.2.1.1 API 6.2.2.1.2 FDF 6.2.2.1.2.1 Solid Dose Formulation 6.2.2.1.2.2 Semi-solid/Liquid dose formulation 6.2.2.1.2.3 Injectable Dose Formulation 6.2.2.1.3 Packaging 6.2.2.2 By Country 6.2.2.2.1 United Kingdom 6.2.2.2.2 Germany 6.2.2.2.3 France 6.2.2.2.4 Italy 6.2.2.2.5 Others 6.2.3 Asia-Pacific 6.2.3.1 By Service Type 6.2.3.1.1 API 6.2.3.1.2 FDF 6.2.3.1.2.1 Solid Dose Formulation 6.2.3.1.2.2 Semi-solid/Liquid dose formulation 6.2.3.1.2.3 Injectable Dose Formulation 6.2.3.1.3 Packaging 6.2.3.2 By Country 6.2.3.2.1 China 6.2.3.2.2 India 6.2.3.2.3 Japan 6.2.3.2.4 Australia 6.2.3.2.5 Others 6.2.4 Latin America 6.2.4.1 By Service Type 6.2.4.1.1 API 6.2.4.1.2 FDF 6.2.4.1.2.1 Solid Dose Formulation 6.2.4.1.2.2 Semi-solid/Liquid dose formulation 6.2.4.1.2.3 Injectable Dose Formulation 6.2.4.1.3 Packaging 6.2.4.2 By Country 6.2.4.2.1 Brazil 6.2.4.2.2 Mexico 6.2.4.2.3 Argentina 6.2.4.2.4 Others 6.2.5 Middle East & Africa 6.2.5.1 By Service Type 6.2.5.1.1 API 6.2.5.1.2 FDF 6.2.5.1.2.1 Solid Dose Formulation 6.2.5.1.2.2 Semi-solid/Liquid dose formulation 6.2.5.1.2.3 Injectable Dose Formulation 6.2.5.1.3 Packaging 6.2.5.2 By Country 6.2.5.2.1 UAE 6.2.5.2.2 Saudi Arabia 6.2.5.2.3 South Africa 6.2.5.2.4 Nigeria 6.2.5.2.5 Rest of Middle East & Africa 7. Competitive Landscape 8. Competitive Intelligence - Company Profiles 8.1 Catalent Inc. 8.2 Recipharm AB 8.3 Jubilant Life Sciences Ltd 8.4 Patheon Inc. 8.5 Boehringer Ingelheim 8.6 Pfizer Centresource 8.7 Aenova 8.8 Famar 8.9 Baxter Biopharma Solutions 8.10 Lonza 9. Investment Scenario 10. Future of the Global Pharmaceutical Contract Manufacturing Market

Catalent Inc, Recipharm AB, Jubilant Life Science, Patheon Inc, Boehringer Ingelheim, Pfizer Centresource, Aenova, Famar, Baxter Biopharma Solutions, Lonza